CXCL10 is Upregulated in Synovium and Cartilage following Articular Fracture†

Running Title: Articular fracture and CXCL10

*Bridgette D. Furman¹, *Collin L. Kent¹, Janet L. Huebner², Virginia B. Kraus², Amy L. McNulty¹, Farshid Guilak³,⁴, Steven A. Olson¹

¹Department of Orthopaedic Surgery, Duke University Medical Center, Durham, NC 27710
²Duke Molecular Physiology Institute, Durham, NC 27701
³Department of Orthopaedic Surgery, Washington University in St. Louis, St. Louis, MO 63110
⁴Shriners’ Hospital for Children-St. Louis, St. Louis, MO 63110

Corresponding author:

Steven A. Olson, M.D.
Duke University Medical Center
Box 3389
Durham, NC 27710
Tel (919) 668-3000
Fax (919) 668-2933
Email: olson016@mc.duke.edu

*These authors contributed equally to this manuscript and share first authorship.

All authors have read and approved the final submitted manuscript. ALM, VBK, FG, and SAO contributed to the research design, interpretation of data, drafting and revising of the manuscript; BDF, CLK and JLK contributed to data acquisition, data analysis, data interpretation, drafting and revising of the manuscript.

†This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/jor.23735]

Received 27 February 2017; Revised 30 August 2017; Accepted 6 September 2017

Journal of Orthopaedic Research
This article is protected by copyright. All rights reserved
DOI 10.1002/jor.23735
ABSTRACT
The objective of this study was to investigate the expression of the chemokine CXCL10 and its role in joint tissues following articular fracture. We hypothesized that CXCL10 is upregulated following articular fracture and contributes to cartilage degradation associated with post-traumatic arthritis (PTA). To evaluate CXCL10 expression following articular fracture, gene expression was quantified in synovial tissue from knee joints of C57BL/6 mice that develop PTA following articular fracture, and MRL/MpJ mice that are protected from PTA. CXCL10 protein expression was assessed in human cartilage in normal, osteoarthritic (OA), and post-traumatic tissue using immunohistochemistry. The effects of exogenous CXCL10, alone and in combination with IL-1, on porcine cartilage explants were assessed by quantifying the release of catabolic mediators. Synovial tissue gene expression of CXCL10 was upregulated by joint trauma, peaking one day in C57BL/6 mice (25-fold) vs. three days post-fracture in MRL/MpJ mice (15-fold). CXCL10 protein in articular cartilage was most highly expressed following trauma compared with normal and OA tissue. In a dose dependent manner, exogenous CXCL10 significantly reduced total matrix metalloproteinase (MMP) and aggrecanase activity of culture media from cartilage explants. CXCL10 also trended toward a reduction in IL-1α-stimulated total MMP activity (p=0.09) and S-GAG (p=0.09), but not NO release. In conclusion, CXCL10 was upregulated in synovium and chondrocytes following trauma. However, exogenous CXCL10 did not induce a catabolic response in cartilage. CXCL10 may play a role in modulating the chondrocyte response to inflammatory stimuli associated with joint injury and the progression of PTA. This article is protected by copyright. All rights reserved

Keywords: cartilage, arthritis, trauma, injury, intra-articular fracture, synovium, inflammation, chemokine
INTRODUCTION

Post-traumatic arthritis (PTA) develops following trauma of weight-bearing joints and accounts for approximately 12% of osteoarthritis (OA) cases of the hip, knee and ankle (1). While the exact etiology of PTA is not yet fully elucidated, it is thought that a major factor involved in the disease progression is inflammation (2). Inflammatory cytokines are elevated following joint injury in humans (3-6) and in animal models (7, 8). Inflammatory cytokines have been shown to upregulate catabolic mediators of cartilage degeneration, such as nitric oxide (NO) and prostaglandin E2, and also extracellular matrix (ECM) degrading enzymes, such as matrix metalloproteases (MMPs) and aggrecanases (9-11). Molecular biomarkers of cartilage degradation products are significantly increased following knee injury in patients (12-15) and are upregulated in animal models of joint injury and in vitro models of injury to articular cartilage (8, 16-18).

Recent studies also suggest that chemokines and their receptors play important roles in rheumatoid arthritis and other forms of inflammatory arthritis. For example, the chemokine CXCL10, or interferon-inducible protein 10 (IP-10), is expressed by synovial cells and fibroblasts (19-21) and upregulated in the serum and plasma of patients with these inflammatory forms of arthritis (22-24). Clinical treatment with anti-rheumatic drugs, including TNF-α blockers, decreased levels of CXCL10 (24, 25). In vitro treatment of synovial cells and human primary fibroblast-like synoviocytes with TNF-α and IL-1β lead to increased levels of CXCL10 (20, 26).

In inflammatory juvenile idiopathic arthritis, CXCL10 plays a role in leukocyte homing to inflamed tissues (27), which may then lead to the perpetuation of chronic inflammation and resulting tissue damage (28). Chemokine receptors including CCR3, the receptor for CXCL10,
are present and upregulated in chondrocytes of OA cartilage (29). Additionally, CXCL10 protein secretion is increased by IL-1 and TNF-α in normal and osteoarthritic (OA) human chondrocytes (30). Synovial fluid CXCL10 levels are correlated with osteoarthritis severity in a rat model of diet-induced obesity (31). However, the effects of CXCL10 on cartilage following joint injury, such as articular fracture, and its role in the development of PTA have yet to be determined.

For this study, we hypothesized that CXCL10 is upregulated following intra-articular fracture and contributes to cartilage degradation associated with PTA. The objectives of this study were three-fold: first, to compare synovial gene expression and serum levels of CXCL10 in C57BL/6 mice that develop PTA following articular fracture and MRL/MpJ mice that are protected from PTA; second, to assess CXCL10 protein expression in normal, OA, and post-traumatic human cartilage; and finally, to determine the effects of exogenous CXCL10 on IL-1-mediated catabolism of cartilage explants.

Materials and Methods

CXCL10 Expression following Articular Fracture in the Mouse.

All procedures were performed in accordance with an IACUC approved protocol. At 16 weeks of age, C57BL/6 (Charles River Labs) and MRL/MpJ (Jackson Laboratory) male mice were sacrificed to represent the pre-fracture condition (n=6 per strain) or received moderate articular fractures of the left tibial plateau, as previously described (7, 32, 33), and then were sacrificed (n=6 per strain) at 0, 1, 3, 5, and 7 days post-fracture.

At sacrifice, joint capsule tissue was harvested with a 3 mm biopsy punch from 6 animals at each time point, as previously described (34). RNA was isolated using a two-step Trizol...
RT-PCR was run on 1µg of RNA in duplicate using SYBR Green Master Mix and the commercially-available RT² Profiler PCR array for mouse inflammatory cytokines (SABiosciences, Qiagen). Relative mRNA for CXCL10 was first normalized to the geometric mean of three housekeeping genes (GAPDH, HPRT1, and HSP90ab1) in that sample and then compared to mRNA expression at pre-fracture within a mouse strain and also between mouse strains at each time point using the 2-ΔΔCt method (7, 35). In accordance with commercial analysis software provided by the manufacturer, results were considered significant if mRNA expression levels were 3-fold different.

Serum was collected at the time of sacrifice. Concentrations of CXCL10 were measured in serum samples using a commercially-available ELISA kit (MCX100; R&D Systems, Minneapolis, MN) and run as directed by the manufacturer. Non-parametric statistical analyses were performed with significance reported at the 95% confidence level. For serum levels of CXCL10, the Mann-Whitney U test was used to compare differences between C57BL/6 and MRL/MpJ strains at each time point, and the Kruskal-Wallis test was used to compare differences with the baseline pre-fracture condition and time post-fracture within a mouse strain. Statistical analysis was performed using Statistica 7 software (StatSoft).

CXCL10 Protein Expression in Human Articular Cartilage.

Cartilage was collected from cadavers with no history of joint injury (Normal; n=7), patients with end stage OA undergoing joint replacement (OA; n=11), and from patients with post-traumatic articular fractures (Trauma; n=29). De-identified human surgical waste tissues for the OA and Trauma samples were collected under an IRB approved exemption. Donor and patient demographics are presented in Table 1.
Immunohistochemistry (IHC) was used to localize CXCL10 protein within the articular cartilage. All tissue samples were formalin-fixed, paraffin-embedded, sectioned at 8 μm, and immunostained for CXCL10. Serial sections were pre-treated with 0.05% proteinase K (Sigma-Aldrich, St. Louis, MO) for 5 minutes at 37°C for antigen retrieval as previously described (36). Endogenous peroxidase was quenched with 3% H2O2 in methanol with 0.1% w/v saponin for membrane permeabilization for 30 minutes. Sections were stained with a polyclonal goat CXCL10 antibody (AF-266-NA, R&D Systems) at 15 μg/mL for 18 hours at 4°C. During every staining protocol, negative controls were run simultaneously by application of 1-2% blocking serum to tissue sections instead of the primary antibody. Chromogenic detection was achieved with DAB substrate (Vectastain, Vector Laboratories, Burlingame, CA), and digital images were obtained. Positive CXCL10 staining in each cartilage zone was noted for sections from all samples. The surface, middle, and deep zones were identified by location and morphology of the chondrocytes. Intensity of positive staining for CXCL10 was assessed qualitatively using a discrete four-point scoring system by two blinded graders and reported as a single consensus score (7).

Effects of Exogenous CXCL10 on Cartilage Explants.

Six cadaveric porcine knees from 2-3 year old skeletally mature female pigs were obtained from a local abattoir shortly after death. Using sterile technique, four 5 mm diameter biopsy punches of cartilage were taken from the femoral condyles of each joint. Explants were washed for one hour in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) with 1,000 units/mL of penicillin/streptomycin/fungizone (Invitrogen). To equilibrate, explants were cultured for 72 hours in DMEM containing 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT), 0.1 mM nonessential amino acids (Invitrogen), 10 mM HEPES...
buffer solution (Invitrogen), 100 units/mL of penicillin/streptomycin/fungizone, and 37.5 µg/mL of L-ascorbic acid 2-phosphate (Sigma-Aldrich) at 37°C and 5% CO2. Media were removed, discarded, and replaced with media containing porcine CXCL10 (ab87388, Abcam, Boston, MA) at concentrations of 0, 1, 10, and 100 ng/mL (n=6 per group). After 72 hours, media were collected and frozen, and cartilage explants were weighed.

To assess the effects of CXCL10 on cartilage explants exposed to a pro-inflammatory stimulus, the following additional experiments were performed. Porcine cartilage explants (5 mm diameter from 6 different joints) were harvested, equilibrated for 72 hours, and then incubated with combinations of 0 or 100 ng/ml of porcine CXCL10 (Abcam) and porcine IL-1α (680-PI-010, R&D Systems) at physiologic concentrations of 0, 10, or 100 pg/ml (n=6 per group) (37, 38). IL-1α was selected due to the observation that porcine cartilage catabolism is more sensitive to IL-1α than IL-1β for physiologic concentrations, i.e., less than 1,000 pg/ml (38). After 72 hours, media were collected and frozen, and cartilage explants were weighed.

For both explant studies, media were assessed for total MMP activity, aggrecanase activity, sulfated glycosaminoglycan (S-GAG) release, and nitric oxide (NO) production. Total specific MMP activity in the culture media was measured using a previously described fluorescence-based assay (39). Aggrecanase-1 (ADAMTS-4) activity was measured in the culture media using a commercially available fluorescent peptide (WAAG-3R, AnaSpec, San Jose, CA) as previously described (40). Total S-GAG release was measured in media using the 1,9-dimethylmethylene blue (DMB) assay (41). Total NO release was determined using an established method that measures the concentration of nitrate and nitrite (NOx) in culture media (42). Data were normalized for the cartilage wet weight and expressed as mean ± SEM. One-way ANOVA was performed using linear trend analysis to assess associations of varying doses.
of exogenous CXCL10 (treated as a categorical variable) with measures of total MMP activity, aggrecanase activity, S-GAG and NO release in media. For the effect of CXCL10 on IL-1-stimulated cartilage explants, statistical analysis was performed using an ANOVA with a Newman-Keuls post-hoc test.

Results

CXCL10 Gene and Protein Expression is Upregulated in Mouse Articular Fracture Model.

Comparing pre- to post-fracture, CXCL10 gene expression was increased in C57BL/6 mice: 13-fold increase within 4 hours of fracture (day 0), a maximum 25-fold increase at day 1, 17-fold increase at days 3 and 5, and 8-fold increase at day 7. In contrast, CXCL10 gene expression was also increased in MRL/MpJ mice, although to a lesser extent: a 5-fold increase on days 0 and 1, a maximum 7-fold increase on day 3, and a 5-fold increase at day 7 (Figure 1 A). Prior to fracture, CXCL10 expression was similar between mouse strains. However, at all post-fracture time points, CXCL10 gene expression in MRL/MpJ mice was lower (range 7 to 15-fold) compared with C57BL/6 mice (Figure 1 A).

Similar to relative gene expression between mouse strains, serum concentrations of CXCL10 were significantly greater in C57BL/6 mice at 1, 3 and 5 days post-fracture compared to MRL/MpJ mice (Figure 1 B). Serum concentrations of CXCL10 varied over time in C57BL/6 mice and trended towards an increase one day post-fracture (Kruskal Wallis, p=0.06). CXCL10 serum concentrations were not significantly different by time post-fracture in MRL/MpJ mice (Kruskal Wallis, p=0.25).
CXCL10 Protein Expression is Upregulated in Human Articular Cartilage following Trauma.

By immunostaining, CXCL10 was detected in chondrocytes in all human cartilage samples. There was minimal CXCL10 in normal cartilage with positive staining only in chondrocytes within the superficial cartilage zone (Figure 2 A). There was slightly more CXCL10 in OA cartilage with localization to the middle and deep cartilage zones (Figure 3 B). CXCL10 was most abundant in trauma cartilage and detected in all cartilage layers (Figure 2 C). Additionally, CXCL10 increased with patient age for both OA and trauma cartilage. Overall, CXCL10 protein expression was highest in cartilage following joint trauma (Figure 2 D).

Anti-Inflammatory Effects of Exogenous CXCL10 on Cartilage Explants.

Exogenous CXCL10 at physiologic concentrations (19, 22, 24) significantly reduced total MMP activity in culture media from cartilage explants in a dose dependent manner (linear trend r = -0.55, p=0.006). CXCL10 also reduced aggrecanase activity in a dose dependent manner (linear trend r = -0.40, p=0.05). Other catabolic measures, including S-GAG release (Figure 3 C: linear trend r = -0.30, p=0.15) and NO release (Figure 3 D: linear trend r = -0.25, p=0.22), were not significantly altered by CXCL10.

Effect of Exogenous CXCL10 on IL-1α-Stimulated Cartilage Explants.

To examine if the observed anti-inflammatory response of CXCL10 could overcome a pro-inflammatory challenge, cartilage explants were cultured with exogenous CXCL10 in combination with physiologic concentrations of IL-1α (38). IL-1α (100 pg/mL) significantly upregulated total MMP activity, S-GAG and NO release (all p<0.001), but not aggrecanase.
activity (p=0.17) in media from cartilage explants (Figure 4). CXCL10 reduced IL-1α stimulated total MMP activity (p=0.09) and S-GAG release (p=0.09) but not NO release (p=0.34).

Discussion

An association of local and systemic CXCL10 has been reported clinically (19, 22, 24, 25) and in animal models of inflammatory arthritis (24, 43, 44). Based on these findings, serum CXCL10 might serve as a clinical marker of disease activity in some forms of arthritis, including PTA. However, the role of chemokines like CXCL10 on cartilage and disease progression following injury is unknown. For this reason, we investigated the endogenous expression of CXCL10 in joint tissues in the context of injury and OA and the impact of exogenous CXCL10 on cartilage inflammation and degradative pathways.

Our results confirm that CXCL10 was endogenously upregulated, most especially by trauma, at both a transcriptional (gene expression) and post-transcriptional (protein by immunohistochemistry observed in all layers of cartilage after fracture and serum analyses by ELISA) level. Although elevated in mouse synovium following articular fracture and in serum of the PTA-prone C57BL/6 mice, CXCL10 was upregulated to a lesser extent in the MRL/MpJ mice that are less susceptible to PTA. These data are consistent with CXCL10 transcriptional regulation by inflammatory cytokines (21, 45). The greater CXCL10 upregulation in the synovium and serum of C57BL/6 mice following articular fracture compared to MRL/MpJ mice may contribute to the increased macrophage infiltration reported in the C57BL/6 mice (7), as CXCL10 and other chemokines have been implicated in immune cell chemotaxis (27, 28). This association of increased CXCL10 expression in synovium and serum with increased synovial inflammation and arthritic changes in the joint is similar to findings for rheumatoid arthritis (19,
20, 22, 24, 46). However, the direct effect of this chemokine on cartilage, or role in cartilage metabolism, has not been established.

Other research has shown that CXCL10 gene expression is upregulated in normal and OA chondrocytes stimulated with IL-1 or TNF-α, and that in response to incubation with exogenous IL-1β, human chondrocytes had increased gene expression of various other chemokines (47). However, the effect of exogenous CXCL10 on cartilage catabolism alone or in combination with pro-inflammatory cytokines has not been reported. In this study, CXCL10 alone or in combination with IL-1α did not induce NO production in cartilage, and consistently and most notably, reduced total MMP and aggrecanase activity. This suggests that CXCL10 may play a role in modulating inflammation following injury or an inflammatory stimulus. A homeostatic role for CXCL10 has already been suggested based on its upregulation in response to *in vitro* exposure of late-stage OA human chondrocytes to the damage-associated molecular pattern (DAMPs) molecule, soluble high mobility groups box-1 (HMGB1) (48).

The acute upregulation of CXCL10 following articular fracture may be part of the natural healing process. CXCL10 has been identified as playing a role in skin fibrosis, wound healing and tissue remodeling by significantly inducing type 1 collagen and hyaluronan production in human dermal fibroblasts (49). It has also been reported that osteochondral healing may be enhanced by CXCL10 through recruitment of subchondral progenitor cells (50). Human osteoclasts have been shown to express high levels of CXCL10 (51), and CXCL10 plays an important role in osteoblast activity through upregulation of enzymes involved in the bone remodeling process. CXCL10 has also been shown to effectively recruit human annulus fibrosus cells *in vitro*, which suggests that CXCL10 is involved in the spontaneous repair of annulus tears in the spine (52). Based on these reports, CXCL10 may enhance healing following an articular
fracture by recruiting cells to the site of the osteochondral injury. Articular fracture induces an inflammatory response in the synovium including infiltration of immune cells and increased cytokine production (6, 53). Results from this study demonstrate articular fracture increases CXCL10 levels. To our surprise, exogenous CXCL10 did not have a catabolic effect on articular cartilage. The complexity of the intra-articular environment following a joint injury, including blood, immune cells, inflammation and altered articulation, makes identification of the etiology of PTA a challenging scientific question. A complex cascade of biomolecular pathways are likely involved, which may include chemokines like CXCL10. More studies are needed to determine the exact role of CXCL10 in the whole joint following injury and in the progression of PTA.

These data in combination suggest that although CXCL10 in joint tissues is upregulated following trauma, CXCL10 does not directly induce catabolism of articular cartilage but may play a role in homeostasis of chondrocytes and modulation of inflammation. The complex signaling that occurs between cartilage, subchondral bone, and synovium is likely to have an important role in maintaining cartilage homeostasis. Identifying key chemokines, like CXCL10, that are upregulated following joint injury may provide new insight into the interaction of joint tissues and opens possibilities of regulating signaling to promote healing and prevent the development of PTA.

ACKNOWLEDGMENTS: Walter Chad Hembree, MD and Adi Kanlic for procuring human cartilage and immunostaining; Stephen Johnson for his technical support; Duke University School of Medicine Anatomical Gifts Program; Duke University URS Independent Study Grant;
Funding Sources: This study was supported by the Arthritis Foundation, NIH grants AG028716, AR55434, AR50245, and AR48852, a VA Rehabilitation Research Service Award, and research grant from DePuy/Synthes.
Table 1. Donor and patient demographics for cartilage samples. Tissue was obtained from donors with no history of joint injury or disease (Normal), patients with end stage osteoarthritis undergoing joint replacement (OA), and patients with articular fracture undergoing surgery (Trauma).

<table>
<thead>
<tr>
<th></th>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>Joint (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>40 – 70</td>
<td>4 / 3</td>
<td>Knee (7)</td>
</tr>
<tr>
<td>OA</td>
<td>53 – 69</td>
<td>5 / 6</td>
<td>Knee (11)</td>
</tr>
<tr>
<td>Trauma</td>
<td>19 – 77</td>
<td>18 / 11</td>
<td>Knee (10), Hip (9), Ankle (7), Elbow (3)</td>
</tr>
</tbody>
</table>
Figure Legends.

**Figure 1.** Gene expression and serum levels of CXCL10 in C57BL/6 and MRL/MpJ mice following fracture. (A) RT-PCR data showing relative change of CXCL10 gene expression in synovial tissue from C57BL/6 mice (black bars) and MRL/MpJ mice (light bars) (n=6 for each strain) following fracture (fx). Top shows fold change from Pre-Fracture (Pre-Fx) for each strain and bottom shows fold change in MRL/MpJ (MRL) strain compared to C57BL/6 (B6) strain. Greater than 3-fold change in expression was considered significant. (B) Serum concentrations of CXCL10 from C57BL/6 (black bars) and MRL/MpJ (light bars) mice following fracture (fx), data presented as mean ± SEM (Mann-U Whitney, *p < 0.05).

**Figure 2.** Immunohistochemistry for CXCL10 in human articular cartilage. Representative images from CXCL10 staining observed in articular cartilage from (A) Normal (n=7), (B) OA (n=11), and (C) Trauma tissue (n=29). Scale bars are 100 μm, with 20x magnification on insert, brown = positive IHC stain, and blue = hematoxylin counterstain. (D) Positive CXCL10 staining was qualitatively graded in the surface, middle and deep zones of the articular cartilage from all samples. Staining was discretely graded on a four-point qualitative scale, (-) to (+++), with (-) indicating minimal staining and (+++) indicating maximal staining in the cartilage zones.

**Figure 3.** Effect of exogenous CXCL10 on cartilage explants. All outcomes measured in media from cartilage explants cultured in different concentrations of CXCL10 (0, 1, 10, 100 ng/ml). Data normalized to wet weight of cartilage and reported as mean ± SEM with statistical analysis using one-way ANOVA with trend analysis. (A) MMP activity in fluorescent units/mg of cartilage (r = -0.55, p = 0.006). (B) Aggrecanase-1 (ADAMTS-4) activity in fluorescent units/mg of cartilage (r = -0.40, p = 0.05). (C) S-GAG release in µg/mg of cartilage (r = -0.30, p = 0.15). (D) NO release in µM/mg of cartilage (r = -0.25, p = 0.22).

**Figure 4.** Effect of exogenous CXCL10 on IL-1α stimulated cartilage explants. All outcomes measured in media from cartilage explants cultured with or without CXCL10 (0, 100 ng/ml) and different physiologic concentrations of IL-1α (0, 10, 100 pg/ml). Data normalized to wet weight of cartilage and reported as mean ± SEM with statistical analysis using ANOVA with Newman-Keuls post-hoc test. (A) Total MMP activity in fluorescent units/mg of cartilage (*p<0.0002, #p=0.09). (B) Aggrecanase-1 (ADAMTS-4) activity in fluorescent units/mg of cartilage (p=0.17). (C) S-GAG release in µg/mg of cartilage (*p<0.0004, †p=0.09). (D) NO release in µM/mg of cartilage (*p<0.0002).
References


Table 1. Donor and patient demographics for cartilage samples. Tissue was obtained from donors with no history of joint injury or disease (Normal), patients with end stage osteoarthritis undergoing joint replacement (OA), and patients with articular fracture undergoing surgery (Trauma).

<table>
<thead>
<tr>
<th></th>
<th>Age (years)</th>
<th>Sex (M/F)</th>
<th>Joint (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>40 - 70</td>
<td>3 / 3</td>
<td>Knee (7)</td>
</tr>
<tr>
<td>OA</td>
<td>53 - 69</td>
<td>5 / 6</td>
<td>Knee (11)</td>
</tr>
<tr>
<td>Trauma</td>
<td>19 - 77</td>
<td>18 / 11</td>
<td>Knee (10), Hip (9), Ankle (7), Elbow (3)</td>
</tr>
</tbody>
</table>
Figure 1
Figure 2
Figure 3
Figure 4